Drug Trial Radar · NCT04643067
Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jun 3, 2021
Primary completion
Jun 29, 2023
Study completion Jun 29, 2023
Sponsor
- Lead sponsor
- Kangpu Biopharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo).
Conditions
- SLE; Drug
Interventions
KPG-818 low dose in phase 1bDrug
Patients received 0.15 mg/day of KPG-818 once daily for up to 14 days.
KPG-818 mid dose in phase 1bDrug
Patients received 0.6 mg/day of KPG-818 once daily for up to 14 days.
KPG-818 high dose in phase 1bDrug
Patients received 2.0 mg/day of KPG-818 once daily for up to 14 days.
KPG-818 ultra-high dose in phase 1bDrug
Patients received 5.0 mg/day of KPG-818 once daily for up to 14 days.
KPG-818 low dose in phase 2aDrug
Patients received 0.15 mg/day of KPG-818 once daily for up to 84 days.
KPG-818 mid dose in phase 2aDrug
Patients received 0.6 mg/day of KPG-818 once daily for up to 84 days.
KPG-818 high dose in phase 2aDrug
Patients received 2.0 mg/day of KPG-818 once daily for up to 84 days.
KPG-818 Placebo in phase 2aDrug
Patients received KPG-818 Placebo once daily for up to 84 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety / Tolerability (Assessed by Adverse Events)Time frame: 4 weeks for phase 1b and 16 weeks for phase 2a
- Phase 1b - PK Assessment: AUC0-last of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: AUC0-∞ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: AUCτ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: Css_max of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: Css_min of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: Tmax of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: t1/2 of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: CL/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 1b - PK Assessment: Vz/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: AUC0-last of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: AUC0-∞ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: AUCτ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: Css_max of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: Css_min of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: Tmax of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: t1/2 of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: CL/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
- Phase 2a - PK Assessment: Vz/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Anniston Medical Clinic
Anniston, Alabama
University of Alabama - Birmingham
Birmingham, Alabama
Clinical Research of West Florida, Inc.
Clearwater, Florida
Hope Clinical Trials, Inc.
Coral Gables, Florida
JY Research Institute Inc
Cutler Bay, Florida
OSIS Clinical Research
Hollywood, Florida
SouthCoast Research Center Inc
Miami, Florida
D & H National Research Centers
Miami, Florida
Charisma Medical and Research Center
Miami Lakes, Florida
San Marcus Research Clinic
Miami Lakes, Florida
Omega Research MetroWest LLC
Orlando, Florida
Clinical Research of West Florida
Tampa, Florida
Oracle Clinical Research
College Park, Georgia
STAT Research
Vandalia, Ohio
Shelby Research LLC
Memphis, Tennessee
Accurate Clinical Management
Houston, Texas
Accurate Clinical Research LLC
Houston, Texas
Sun Research Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.